vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and CareTrust REIT, Inc. (CTRE). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $134.9M, roughly 2.0× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 1.4%, a 81.2% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 9.7%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
ACAD vs CTRE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $134.9M |
| Net Profit | $3.6M | $111.3M |
| Gross Margin | — | — |
| Operating Margin | -1.7% | — |
| Net Margin | 1.4% | 82.5% |
| Revenue YoY | 9.7% | 55.1% |
| Net Profit YoY | — | 113.5% |
| EPS (diluted) | $0.02 | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | — | ||
| Q4 25 | $284.0M | $134.9M | ||
| Q3 25 | $278.6M | $132.4M | ||
| Q2 25 | $264.6M | $112.5M | ||
| Q1 25 | $244.3M | $96.6M | ||
| Q4 24 | $259.6M | $86.9M | ||
| Q3 24 | $250.4M | $77.4M | ||
| Q2 24 | $242.0M | $68.9M |
| Q1 26 | $3.6M | — | ||
| Q4 25 | $273.6M | $111.3M | ||
| Q3 25 | $71.8M | $74.9M | ||
| Q2 25 | $26.7M | $68.5M | ||
| Q1 25 | $19.0M | $65.8M | ||
| Q4 24 | $143.7M | $52.1M | ||
| Q3 24 | $32.8M | $33.4M | ||
| Q2 24 | $33.4M | $10.8M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | -1.7% | — | ||
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | 58.1% | ||
| Q2 25 | 12.2% | 61.3% | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | 43.0% | ||
| Q2 24 | 12.6% | 15.1% |
| Q1 26 | 1.4% | — | ||
| Q4 25 | 96.3% | 82.5% | ||
| Q3 25 | 25.8% | 56.6% | ||
| Q2 25 | 10.1% | 60.9% | ||
| Q1 25 | 7.8% | 68.1% | ||
| Q4 24 | 55.4% | 60.0% | ||
| Q3 24 | 13.1% | 43.2% | ||
| Q2 24 | 13.8% | 15.6% |
| Q1 26 | $0.02 | — | ||
| Q4 25 | $1.61 | $0.52 | ||
| Q3 25 | $0.42 | $0.35 | ||
| Q2 25 | $0.16 | $0.35 | ||
| Q1 25 | $0.11 | $0.35 | ||
| Q4 24 | $0.86 | $0.30 | ||
| Q3 24 | $0.20 | $0.21 | ||
| Q2 24 | $0.20 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $198.0M |
| Total DebtLower is stronger | — | $894.2M |
| Stockholders' EquityBook value | — | $4.0B |
| Total Assets | $1.6B | $5.1B |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | $198.0M | ||
| Q3 25 | $258.0M | $712.5M | ||
| Q2 25 | $253.6M | $306.1M | ||
| Q1 25 | $217.7M | $26.5M | ||
| Q4 24 | $319.6M | $213.8M | ||
| Q3 24 | $155.1M | $377.1M | ||
| Q2 24 | $177.1M | $495.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $894.2M | ||
| Q3 25 | — | $893.8M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $822.1M | ||
| Q4 24 | — | $396.9M | ||
| Q3 24 | — | $396.7M | ||
| Q2 24 | — | $671.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $4.0B | ||
| Q3 25 | $917.3M | $4.0B | ||
| Q2 25 | $822.4M | $3.3B | ||
| Q1 25 | $765.2M | $2.9B | ||
| Q4 24 | $732.8M | $2.9B | ||
| Q3 24 | $577.2M | $2.4B | ||
| Q2 24 | $516.7M | $1.9B |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.3B | $5.1B | ||
| Q2 25 | $1.2B | $4.7B | ||
| Q1 25 | $1.1B | $3.9B | ||
| Q4 24 | $1.2B | $3.4B | ||
| Q3 24 | $976.9M | $2.9B | ||
| Q2 24 | $914.1M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $394.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.54× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $394.0M | ||
| Q3 25 | $74.3M | $100.9M | ||
| Q2 25 | $64.0M | $100.8M | ||
| Q1 25 | $20.3M | $71.4M | ||
| Q4 24 | $40.4M | $244.3M | ||
| Q3 24 | $63.2M | $67.2M | ||
| Q2 24 | $25.0M | $53.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 3.54× | ||
| Q3 25 | 1.03× | 1.35× | ||
| Q2 25 | 2.40× | 1.47× | ||
| Q1 25 | 1.07× | 1.08× | ||
| Q4 24 | 0.28× | 4.68× | ||
| Q3 24 | 1.93× | 2.01× | ||
| Q2 24 | 0.75× | 4.92× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
